Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Nov;60(5):767–769. doi: 10.1038/bjc.1989.356

Cisplatin/carboplatin cross-resistance in ovarian cancer.

M E Gore 1, I Fryatt 1, E Wiltshaw 1, T Dawson 1, B A Robinson 1, A H Calvert 1
PMCID: PMC2247292  PMID: 2803953

Abstract

Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.

Full text

PDF
767

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker G. H., Wiltshaw E. Use of high dose cis-dichlorodiammine platinum (II) (NSC--119875) following failure on previous chemotherapy for advanced carcinoma of the ovary. Br J Obstet Gynaecol. 1981 Dec;88(12):1192–1199. doi: 10.1111/j.1471-0528.1981.tb01196.x. [DOI] [PubMed] [Google Scholar]
  2. Boven E., van der Vijgh W. J., Nauta M. M., Schlüper H. M., Pinedo H. M. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res. 1985 Jan;45(1):86–90. [PubMed] [Google Scholar]
  3. Bruckner H. W., Cohen C. J., Wallach R. C., Kabakow B., Deppe G., Greenspan E. M., Gusberg S. B., Holland J. F. Treatment of advanced ovarian cancer with cis=dichlorodiammineplatinum(II): poor-risk patients with intensive prior therapy. Cancer Treat Rep. 1978 Apr;62(4):555–558. [PubMed] [Google Scholar]
  4. Burchenal J. H., Kalaher K., Dew K., Lokys L. Rationale for development of platinum analogs. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1493–1498. [PubMed] [Google Scholar]
  5. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  6. Evans B. D., Raju K. S., Calvert A. H., Harland S. J., Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983 Nov;67(11):997–1000. [PubMed] [Google Scholar]
  7. Knox R. J., Friedlos F., Lydall D. A., Roberts J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972–1979. [PubMed] [Google Scholar]
  8. Lewis A. D., Hayes J. D., Wolf C. R. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis. 1988 Jul;9(7):1283–1287. doi: 10.1093/carcin/9.7.1283. [DOI] [PubMed] [Google Scholar]
  9. Ozols R. F., Ostchega Y., Curt G., Young R. C. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol. 1987 Feb;5(2):197–201. doi: 10.1200/JCO.1987.5.2.197. [DOI] [PubMed] [Google Scholar]
  10. Ozols R. F., Ostchega Y., Myers C. E., Young R. C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985 Sep;3(9):1246–1250. doi: 10.1200/JCO.1985.3.9.1246. [DOI] [PubMed] [Google Scholar]
  11. Stanhope C. R., Smith J. P., Rutledge F. Second trial drugs in ovarian cancer. Gynecol Oncol. 1977 Mar;5(1):52–58. doi: 10.1016/0090-8258(77)90007-5. [DOI] [PubMed] [Google Scholar]
  12. Wiltshaw E., Evans B., Rustin G., Gilbey E., Baker J., Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol. 1986 May;4(5):722–729. doi: 10.1200/JCO.1986.4.5.722. [DOI] [PubMed] [Google Scholar]
  13. Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]
  14. Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985 Sep;12 (Suppl A):67–71. doi: 10.1016/0305-7372(85)90020-9. [DOI] [PubMed] [Google Scholar]
  15. Young R. C., Von Hoff D. D., Gormley P., Makuch R., Cassidy J., Howser D., Bull J. M. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1539–1544. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES